Related Experiment Video
Updated: Aug 17, 2026

Sedimentation Equilibrium of a Small Oligomer-forming Membrane Protein: Effect of Histidine Protonation on Pentameric Stability
Published on: April 2, 2015
Stability studies of hydralazine hydrochloride in aqueous solutions
Abstract:
The hydrolysis kinetics of hydralazine hydrochloride was studied at pH 1 to 12 at 35 degrees, 50 degrees, and 70 degrees C. The hydrolysis takes place by water attack on the dicationic and the cationic forms of the drug. In addition there is hydroxyl attack on the cationic and the neutral forms of the drug. The drug is not subject to attack by acetate and carbonate buffers, but its decomposition is catalyzed by HPO4 = of the H2PO4-, HPO4 = buffer system. The hydrolysis rate follows first order kinetics under nitrogen, at constant pH, temperature, and buffer concentration. The pH profile indicates that hydralazine has maximum stability near pH 3.5. The drug decomposes to phthalazine and other products. The Arrhenius activation energy was found to be 17.9 kcal/mol at pH 3.5 and the time required for 10% loss (t0.9) was estimated from the Arrhenius parameters to be 1.56 years at 25 degrees C.
Related Concept Videos
Chemical Equilibria: Systematic Approach to Equilibrium Calculations
The first step is to identify all the chemical reactions involved, The...
Titration of a Weak Base with a Strong Acid
Using the ICE table and substituting the Kb value, we calculate the initial pH of 50 mL of 0.1 M ammonia to be 11.11. Addition of 25 mL of 0.1 M hydrochloric acid to this solution of ammonia results in a buffer with an equal concentration of ammonia and ammonium ions. The pH of this buffer can be calculated by substituting these...
Titration in Nonaqueous Solvents
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Drug Product Stability
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

